Comparative Pharmacology
Head-to-head clinical analysis: EVZIO versus VIVITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVZIO versus VIVITROL.
EVZIO vs VIVITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Naltrexone, as the active moiety of VIVITROL, is a competitive antagonist at opioid receptors (mu, kappa, and delta), blocking the euphoric effects of alcohol and opioids. It also modulates the hypothalamic-pituitary-adrenal axis and dopamine pathways implicated in alcohol craving.
2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.
380 mg intramuscularly every 4 weeks, alternating gluteal injections.
None Documented
None Documented
The terminal elimination half-life of naloxone in adults is approximately 1-2 hours. In neonates, half-life may be prolonged to 3-4 hours. Clinical context: Short half-life necessitates repeated dosing or continuous infusion for sustained opioid reversal, especially with long-acting opioids.
Naltrexone terminal half-life: 4-13 hours (mean 9.7 h). Active metabolite 6-β-naltrexol: 10-15 hours. Clinically, naltrexone concentrations are sustained for ~30 days after IM injection.
Naloxone undergoes extensive hepatic metabolism primarily via glucuronidation, with approximately 70% excreted in urine as naloxone-3-glucuronide. About 25% is excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Naltrexol (6-β-naltrexol) and naltrexone: primarily renal (60-70% as metabolites, <5% as unchanged drug); biliary/fecal (minor route, <10%).
Category C
Category C
Opioid Antagonist
Opioid Antagonist